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Introduction
Pediatric rheumatologists use musculoskeletal ultrasound
(MSUS) in everyday practice as a simple, painless and
inexpensive tool for detecting synovitis. Along with
MSUS, Juvenile Arthritis Disease Activity Score (JADAS)
was proven to be valid for clinical assessment. In JIA
patients with mono- or oligoarthritis who are inade-
quately responding to conventional therapy, but do not
meet criteria for biological therapy, intraarticular inflixi-
mab could be therapy of choice. Since this therapeutic
option is not routinely used, there is a need for a contin-
uous follow-up, in which MSUS and JADAS could have
great value.
Objectives
To assess the efficacy of intraarticular infliximab injec-
tions in patients with juvenile idiopathic arthritis (JIA)
using MSUS and juvenile arthritis disease activity score
(JADAS).
Methods
IA infliximab was administered in 22 joints of 14
patients diagnosed with JIA according to ILAR classifi-
cation criteria. All patients received first and second line
therapy (NSAID, DMARD, corticosteroids systemic and
IA). None of the patients fulfilled criteria for treatment
with biologic therapeutics, but were resistant to
DMARD’s. Intraarticular infliximab (25 mg or 50 mg
per joint) was administered.
The patients were monitored by monthly assessment
using JADAS (number of active joints, pain assessed by
patient/parent an physician (VAS), ESR) and MSUS.
The MSUS assessment included Omeract semiquantita-
tive grades (0–3 grades) for both B-mode and Power-
Doppler (PD) and 12 patients were examined using 3D/
4D US. We used paired samples T-test for comparing
JADAS before and after the treatment.
Results
At the point of IA injections all 22 joints showed grade 2-3
synovitis in B mode and increased PD signal (2-3/3). The
mean value of JADAS was 17.31 (± 2.78). At the end of
the follow-up period (mean time 7.07 months, range 6-10
months) the mean value of JADAS was 5.66 (± 3.52).
There was also improvement in MSUS with 0-1 grade
synovitis without effusion in B mode and PD signal
decreased to 0-1/3. The deference in JADAS was statisti-
cally significant (p< 0.001). However, 3/14 patients subse-
quently flared (mean time 6-8 months) and fulfilled
criteria for systemic biologic therapy. Two of those three
patients received lower IA dose of infliximab (25 mg per
joint).
Conclusion
IA infliximab should still be considered as a therapy
option in selected children with therapy resistant, isolated
mono/oligoarticular JIA. The effect of IA therapy could
be easily monitored both by MSUS and JADAS.
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